BreastCocktail(CKHMW/p63+CK7/8/18)iscomprisedofmousemonoclonalanti-CKHMWandanti-p63antibodiesaswellasrabbitmonoclonalanti-CK7andmousemonoclonalanti-CK8/18antibodies.CKHMW(highmolecularweightcytokeratin)isexpressedinthecytoplasmofbasalcellsandmyoepitheliumofbreasttissue(1-4).p63isatranscriptionfactorpresentinthenucleiofmyoepithelialcells(2,4).Incontrast,CK7,CK8andCK18arelowmolecularweightcytokeratinsprimarilyexpressedinluminalcellsofthebreast(1-3).
CKHMW,p63,CK7,CK8andCK18haveroutinelybeenusedasapanelofIHCMarkerstocomplementmorphologicalevaluationintheassessmentofbreastlesions,duetothedifferentialexpressionoftheluminalvs.basalandmyoepithelialmarkers(1-5).Casesofusualductalhyperplasia(UDH)havebeenassociatedwithexpressionofthebasalcellmarkers,intermixedwithcellsexpressingthekeratinsofluminalcells(1-2,6-10).Mostcasesofatypicalductalhyperplasia(ADH)andlowgradeductalcarcinomainsitu(LG-DCIS)werenegativeforthebasalmarkersandexhibitedanimmunophenotypeindicativeofluminalcells(1,5-8).Additionally,thebasalphenotypehasbeenshowntobecharacterizedbyluminalexpressionofthebasalandmyoepithelialmarkers,usingacocktailofCKHMWandp63(11-13).
IHC,usingCKHMW,p63,CK7,CK8andCK18antibodies,evaluatedincombinationwithhematoxylinandeosin(H&E),hasbeenshowntosignificantlyincreaseinter-observeragreementamongstpathologists,comparedtoH&Ealone(14).
| Format | VP |
|---|---|
| Volume | 6.0ml |
| ByLetter | B |
| IntendedUse | IVD |
| Antigen | CKHMW,CK7,CK8/18,p63 |
References:
1.HicksDG.Immunohistochemistryinthediagnosticevaluationofbreastlesions.ApplImmunohistochemMolMorph.2011;19:501-5.
2.MoriyaT,etal.Newtrendsofimmunohistochemistryformakingdifferentialdiagnosisofbreastlesions.MedMolMorphol.2006;39:8-13.
3.YehIT,MiesC.Applicationofimmunohistochemistrytobreastlesions.ArchPatholLabMed.2008;132:349-57.
4.LerwillMF.Currentpracticalapplicationsofdiagnosticimmunohistochemistryinbreastpathology.AmJSurgPathol.2004;28:1076-91.
5.MoriyaT,etal.Usefulnessofimmunohistochemistryfordifferentialdiagnosisbetweenbenignandmalignantbreastlesions.BreastCancer.2009;16:173-8.
6.OtterbachF,etal.Cytokeratin5/6immunohistochemistryassistsindifferentialdiagnosisofatypicalproliferationsofthebreast.Histopathology.2000;37:232-40.
7.Lacroix-TrikiM,etal.Valueofcytokeratin5/6immunostainingusingD5/16B4antibodyinthespectrumofproliferativeintraepitheliallesionsofthebreast.Acomparativestudywith34betaE12antibody.VirchowsArch.2003;442:548-54.
8.BoeckerW,etal.Usualductalhyperplasiaofthebreastisacommittedstem(Progenitor)celllesiondistinctfromatypicalductalhyperplasiaandductalcarcinomainsitu.JPathol.2002;198:458-67.
9.KooJS,etal.ComparisonofImmunohistochemicalstaininginbreastpapillaryneoplasmofcytokeratin5/6andp63incoreneedlebiopsiesandsurgicalexcisions.ApplImmunohistochemMolMorph.2012;20:108-15.
10.IchiharaS,etal.Doubleimmunostainingwithp63andhighmolecular-weightcytokeratinsdistinguishesborderlinepapillarylesionsofthebreast.PathInt.2007;57:126-32.
11.LivasyCA,etal.Phenotypicevaluationofthebasal-likesubtypeofinvasivebreastcarcinoma.ModPathol.2006;19:264-71.
12.LaaksoM,etal.Cytokeratin5/14-positivebreastcancer:truebasalphenotypeconfinedtoBRCA1tumors.ModPathol.2005;18:1321-8.
13.BhargavaR,etal.CK5ismoresensitivethanCK5/6inidentifyingthe“basal-like”phenotypeofbreastcarcinoma.AmJClinPathol.2008;130:724-30.
14.JainRK,etal.Atypicalductalhyperplasia:interobserverandintraobservervariABIlity.ModPathol.2011;24:917-23.
15.CenterforDiseaseControlManual.Guide:SafetyManagement,NO.CDC-22,Atlanta,GA.April30,1976“DecontaminationofLaboratorySinkDrainstoRemoveAzideSalts.”
16.ClinicalandLaboratoryStandardsInstitute(CLSI).ProtectionofLaboratoryWorkersfromOccupationallyAcquiredInfections;ApprovedGuideline-FourthEditionCLSIdocumentM29-A4Wayne,PA2014.
